Entrepreneur
Tackling women’s mental health with music and tech

By Tuned Global
Mental health problems affect both men and women, but not in equal measure. According to the Mental Health Foundation, one in five adults has a common mental health condition: about 24 per cent of women and 15 per cent of men.
The Mind Organisation also reveals women are more likely to have suicidal thoughts and to make suicide attempts than men. So how can music therapy help?
At a recent industry event, audiences attending a session on music in the medicine and research space gained insights into the therapeutic benefits of music, such as treating conditions including dementia, Parkinson’s disease, PTSD and ADHD.
Three experts sat down to discuss this exciting and complex space and to explore how in trying to bring these treatments to patients or the broader market, the not-so-common intersection of medtech and music surfaces a number of challenges.
How AI can strengthen music therapies

Felicity Baker
Music therapy itself is not new, and therapists have been delivering such interventions in one-on-one sessions and small groups for decades.
The exciting prospect highlighted during the session was that technology and AI can now enable this at scale and with evidence-based approach.
If more people can gain access to music treatment through technology, there is the potential to decrease medication intake, reduce healthcare costs and improve outcomes.
However, scaling these therapies does introduce new considerations and challenges that traditional clinical settings have not had to face.
Felicity Baker is a music therapist, professor at the University of Melbourne and Founder of Matchplus.ai, a sensor-based AI solution that detects early physiological markers of agitation and delivers personalised music interventions to improve the wellbeing of people living with dementia and other cognitive conditions.
With over three decades of experience in dementia care and music therapy, Baker is leading this project at prototype stage to reduce distress, medication reliance and create a more enabling environment for individuals with cognitive decline.
Having successfully secured USD $1.3m from Google.org (the philanthropic arm of Google LLC) to develop scalable technology, Baker has become one of just 15 recipients worldwide from more than 800 applications.
“We’re using wearables to actually develop algorithms that can predict when someone is going to start wandering or is going to get up and have a fall or hit another resident in the nursing home,” she said.
“We’ve got it down to between five and 15 minutes, so a carer or family member can anticipate that something’s going to happen.”
Baker said using AI to help preempt when to use music was one thing, but then what order the music should come in, what kind of music and how to be sensitive to the specific symptoms of people with dementia created further challenges they continue to work on.
Simone Dalla Bella, co-director of the BRAMS laboratory at the University of Montreal is conducting research focused on rhythm interventions for patients with various disorders, including Parkinson’s disease.

Simone Dalla Bella
The interventions include rhythmic serious games such as Beat Workers, and mobile apps such as BeatMove, developed by the start-up BeatHealth that Dalla Bella co-founded.
For example, BeatMove can adjust music tempo to help Parkinson’s patients walk more effectively.
“Imagine that you have music in the background that you chose, and the music is going a bit faster than you, so it motivates you to run a bit faster.
“But then if you’re tired and you slow down, the music will follow you gently as if you were running or walking with a theoretical partner,” he said.
“A clinical trial is currently ongoing in France to test a large group of patients with Parkinson’s who basically take the app outside in a park, they use it, and we are seeing beneficial effects of that kind of intervention.”
Navigating music licensing challenges
The prospect of music-powered therapy is rather inspiring and life-affirming. Providing outcomes for patients with debilitating conditions in a non-invasive way is certainly a noble cause for academics and entrepreneurs alike to take up.
However, what many might not have considered is how these medical applications acquire and manage music rights.
Virginie Chelles, VP and Global Head of Marketing and Communications for music licensing and technology company Tuned Global, described the complexity facing these innovators.
In working with medical technology clients, Chelles highlighted that while founders deeply understand the science and tech behind their products and projects, they often have no knowledge of music industry operations.
“When it comes to us, there is a whole new industry, being the music industry which has little or no connection with the medical industry, [which in itself also] has a lot of regulation,” she said.
In the medical music space, Tuned Global currently works with MediMusic, a UK startup that uses AI to analyse brain responses and select music for anxiety and pain management.
Companies like MediMusic are obviously performing powerful and important work, but in cases where they are not up to speed on all of the requirements to correctly licence music, they are adding layers of risk to an already compliance-heavy environment.

Virginie Chelles
“They’re dealing with the legal side of medicine in being able to have it delivered in NHS Hospitals in the UK, and going for trials and all that is involved.
“There is a lot of paperwork to do there,” Chelles said. “But then, if they play the wrong track, [a] track that was not licensed, the business is in trouble.”
“[They would be looking at lawsuits], and they wouldn’t be paying the rights to the right people. There are master rights, there’s publishing rights. [So they think], ‘How do I do that? How do I find the right tracks?’.”
Often in these kinds of apps, an AI personalisation solution will drive the selection of tracks that resonate with certain patients, so another challenge for medtech clients in knowing the extent of what other tracks they will need access to.
Companies must also consider whether their licenses permit training medical algorithms on music assets.
“Thousands of tracks are released every day, and [if you look at what’s being produced] with AI. It’s even more,” she said.
“Many companies don’t need millions of tracks. If you work on dementia, just working on a back catalogue, like the catalog that makes sense for these people when they were in their 20s.
“For us, it helped us to understand what you need to license the right catalog, rather than millions of tracks, because accessing millions of tracks is a lot of money in storage and in processing.”
Understanding music licensing early in the innovation process
For medtech companies wanting to leverage music, Chelles was direct about the challenges and decisions they face when they first approach music licensing.
A lot of consideration needs to be made about how much music they need, what kind, whether they need commercial music or production music and more.
When MediMusic first engaged Tuned Global, these considerations presented a big challenge.
“Because licensing music is not a science. It’s not predictable, but we can definitely help,” she said.
Elaborating further, Chelles said that companies tended to be more successful when they addressed music licensing early in development rather than treating it as an afterthought.
“It’s going to take as much time to build the music and the licensing and compliance technology as building your medical device or app or science behind it,”
“Talk to a music expert early on, it can be us, but it can also be entertainment lawyers or licensing specialists that are going to be able to help from the beginning … to just understand what it is about.
“We can also help them to build their business case to pitch to those labels, because this can be quite strategic depending on the label and their current objectives.
“Making big pitches without understanding them or the broader environment could cost a lot of time and money if they don’t sign you up right away.
“Being able to demonstrate and communicate value in this industry on the industry’s terms is really important for success, so if you can work with people that have these relationships and can engage with them it’s very helpful.”
Working with an established music technology company can help medtech startups navigate label negotiations. Labels recognise that companies already working with licensing specialists have typically secured funding and understand the commercial requirements.
“[The labels are] like, okay, they are legit, because if Tuned Global can work with them, they already have the funding and they understand what they’re doing,” Chelles said.
Securing licensing agreements is only the first step. Companies then need backend technology to access the actual tracks.
Tuned Global maintains 190 million tracks, with the catalog growing daily.
Companies must negotiate separately with both master rights holders (the record labels) and publishers who represent musicians and writers.
Commercialising research and innovation
Neither researcher came from a background that prepared them for music industry negotiations.
Despite publishing in The Lancet and Nature and securing major medical research grants, Baker found music licensing remained unfamiliar territory.
Dalla Bella received more than $USD 3.5m in European research funding but similarly had no training in navigating music rights.
Startup activity at universities is growing, but this has not always been the case.
Baker noted that while the institutions themselves were very supportive and really wanted to push research innovations into the market, there still exists some commercialisation stigmas among some researchers.
“For some researchers, commercialising your research is kind of almost like a dirty word.
“To them it’s like you’re not being true to the science if you want to actually make a company and do something with this,” she said.
Dalla Bella described how moving from pure research into commercial applications required stepping outside his comfort zone.
“Sometimes in science, we’re very closed, right?
“We do work just in science, in our niche, we are happy with what we do, but then you have to go beyond your comfort zone to start to work with engineers and start to work with a startup company,” he said.
“[I’ve seen for a lot of people] it took time to build this collaboration, this common language, and to be able to work together. After a certain amount of time, you discover the real potential of doing that.”
The future of tech powered music therapies
The medical music technology sector is an exciting and expanding space.
As more innovators enter the industry, the intersection between healthcare regulation and music licensing will likely require more standardised frameworks and understanding of the complexities so they aren’t bogged down or exposed to complications that could cut their journey to provide care short.
For now, companies navigating both industries must build relationships with experts in each domain.
The medical science may be groundbreaking, but without proper music licensing infrastructure, therapeutic applications cannot reach patients or compensate the artists whose work makes treatment possible.
About Tuned Global
Tuned Global is the leading data-driven cloud and software platform that empowers businesses to integrate commercial music into their apps or launch complete streaming experiences using advanced APIs, real-time analytics, licensing solutions, and customisable white-label apps.
Our turnkey solutions for music, audio, and video — coupled with a broad ecosystem of third-party music tech integrations — make us the most comprehensive platform for powering any digital music project. We streamline complexities in licensing, rights management, and content delivery, enabling rapid innovation and bringing new ideas to life.
Since 2011, we’ve supported 40+ companies in 70+ countries — across telecom, fitness, media, aviation, and more — to deliver innovative music experiences faster and more cost-effectively.
For more information, visit www.tunedglobal.com.
Entrepreneur
Peripear wins Innovate UK Women in Innovation Award

Medtech startup Peripear has won an Innovate UK award for developing a wearable designed to prevent perineal trauma during childbirth.
The Oxford-based company is developing a hands-free warm compress device for use on the perineum during the second stage of labour.
Peripear describes its product as the world’s first automated perineal thermotherapy wearable, designed to prevent perineal trauma during childbirth.
The device is intended to reduce severe tearing and episiotomies while improving maternal comfort.
Peripear has secured an Innovate UK Women in Innovation Award and a £74,974 grant.
The funding will support further product development ahead of the company’s planned first-in-human study.
Nina van Schaick, co-founder and chief operating officer of Peripear and midwife, said: “I’m sure I wasn’t the only one to see this gap.
“I was incredibly lucky to meet my co-founder, Eviatar Natan, right as my frustration about the lack of translation of evidence into practice had peaked.
“There was a proven mechanism that could reduce injuries occurring in up to 90 per cent of vaginal births, and it was being left out of clinical pathways simply because no standardised tool existed to deliver it.
“I’m a farmer’s granddaughter, and when I started practising over 14 years ago, I asked: where is the tool I need to implement this evidence? I looked around and realised we were still asking clinicians to improvise.
“Peripear is what happens when the person who has lived the problem, both personally and professionally, meets the person who can help her build the solution.”
Entrepreneur
Applications close August 18 for Women’s Health Innovation Summit 2026 Innovation Showcase

The Women’s Health Innovation Summit (WHIS) has reminded startups that applications for its 2026 Innovation Showcase close on Tuesday, August 18.
The Showcase gives early and growth-stage companies the opportunity to pitch live on stage to the most influential audience in women’s health, at a summit that convenes more than 1,000 senior decision-makers from across the ecosystem, including payers, providers, pharma, and investors.
Now in its eighth year, WHIS takes place October 13–15, 2026 at Encore Boston Harbor.
The event has built a reputation as the leading platform uniting the full women’s health ecosystem, from health systems and health plans to pharmaceutical leaders and the investors funding the next wave of innovation in the space.
A Direct Line to Funding, Partnerships and Adoption
Companies selected for the Innovation Showcase will present directly to an audience with the capital, clinical expertise and commercial relationships to move deals forward.
Past participants have gone on to secure investor introductions, commercial partnerships and clinical collaborations that started as presentations on the WHIS stage and turned into signed agreements.
Applications Reviewed by an Expert Selection Committee
Submissions are being reviewed by a selection committee of leading investors and industry operators, including:
- Parambir Bhangu, Executive Director, External Innovation & Emerging Science, Organon
- Elizabeth Bailey, Co-Founder & Managing Partner, Foreground Capital
- Karla Loken, Founder, Loken and Associates
- Mané Mikayelyan, Associate Partner, DeciBio
- Anna Valcheva, Founder, Managing Director & CEO, Astra Ventures
- Azin Radsan van Alebeek, Co-founder & General Partner, Emmeline Ventures
WHIS is where the women’s health ecosystem comes together to get deals done,” said Poppy Howard-Wall, Event Director of WHIS.
How to Apply
Early and growth-stage companies across digital health, therapeutics, diagnostics, med device and consumer health are encouraged to apply before the August 18 deadline.
Full details and the application form are available at whisusa.com/attend/start-ups.
Events
Women’s Health Week Europe 2026 releases fully populated agenda ahead of October summit

Women’s Health Week Europe 2026 has released its fully populated speaker and session lineup ahead of the event’s return to The Emirates Stadium in London on 7–8 October, with 80+ speakers now confirmed across two dedicated stages.
The programme
The agenda runs across two dedicated stages in parallel, plus two pitch competitions across both days.
The Global Stage opens with a keynote from Merete Clausen (EIF) before moving into sessions on funding trends, AI, the gender data gap, the wearable revolution, and European policy.
Standout sessions include The Age of Digital TransformAItion featuring Nichole Young-Lin (Google), Frida Polli (MIT), and Sapna Shah (Sie Ventures); Lone Wolf or Pack Leader on collaboration versus fragmentation, with Eirini Rapti (Inne), Tatum Getty (Thena Capital), Novo Nordisk, and Jen Roberts-Woods (Borski Fund); and a live debate on whether the women’s health label helps or hinders founders. Day one closes with a keynote from Alison Cave, Chief Safety Officer at the MHRA.
The Scale Stage runs a practical playbook track in parallel, with sessions covering regulatory approval pathways, international expansion, the founder’s legal playbook, PR strategy, and implementing AI into a women’s health business.
The Reverse Pitch flips the usual format: investors and corporates pitch the room on what they are actively looking to fund, acquire, or partner on right now.
Register here and receive a 15% discount on tickets. Redeem with code FEMTECHWORLD
Pitch competitions
The WHW Europe pitch competitions are back, taking place in front of the audience across both days on the mainstage. 16 finalists will compete across two categories: Consumer & Tech on day 1 and Medical Devices & Therapeutics on day 2.
Any company treating a condition that affects women exclusively, differently, or disproportionately is eligible to apply.
Applications and close 28 August 2026.
Previous alumni include Circe, who secured £100k from Innovate UK, BoobyBiome, who closed a £2.5M seed round post-WHW Europe, and Amilis, who secured £1M at London Tech Week after winning at WHW USA 2026.
Entrepreneur2 weeks agoApplications close August 18 for Women’s Health Innovation Summit 2026 Innovation Showcase
Menopause2 weeks agoThird of women unaware of perimenopause mental health impact
Fertility6 days agoChelsea FC Women to launch first-of-its-kind player fertility fund
Events2 weeks agoWomen’s Health Week Europe 2026 releases fully populated agenda ahead of October summit
Mental health1 week agoMenopausal hormone therapy may lower dementia risk, study suggests
Diagnosis2 weeks agoWe are wrapping our children in plastic and calling it care
Pregnancy2 weeks agoChemicals in plastics may be linked to high blood pressure during pregnancy
News2 weeks agoWomen with endometriosis face 46% higher risk of type 2 diabetes – study













1 Comment